Mind Medicine (MindMed) Inc N.MMED.WA

Primary Symbol: MNMD Alternate Symbol(s): N.MMED.WS | N.MMED.WR | N.MMED

Healthcare

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).

NDAQ:MNMD - Post by User

Mind Medicine (MindMed) Inc > Shorting

<< Previous

Bullboard Posts

Next >>

Comment by Superss63on Apr 29, 2021 8:14am

173 Views

Post# 33089424

RE:RE:RE:RE:RE:RE:RE:RE:Shorting

TeddyTenBags wrote: Courage? How about putting your money where your mouth is. Sounds like we've got a pumping bagholder who's upset that he bought at $7.

Less than 1% of the total share count is shorted.

Yeah, okay,

% of Vol Shorted
Apr 28 33.57

<< Previous

Bullboard Posts

Next >>

Gold vs. bitcoin, where should you invest?